{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:11:54Z","timestamp":1790269914325,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","primarycare.theclinics.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Primary Care: Clinics in Office Practice"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.pop.2016.07.011","type":"journal-article","created":{"date-parts":[[2016,11,18]],"date-time":"2016-11-18T00:38:19Z","timestamp":1479429499000},"page":"589-605","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Polycythemia and Thrombocytosis"],"prefix":"10.1016","volume":"43","author":[{"given":"Aric","family":"Parnes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Ravi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.pop.2016.07.011_bib1","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/MOH.0000000000000216","article-title":"Contemporary approach to essential thrombocythemia and polycythemia vera","volume":"23","author":"Aruch","year":"2016","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.pop.2016.07.011_bib2","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s11899-014-0228-z","article-title":"Epidemiology of MPN: what do we know?","volume":"9","author":"Anderson","year":"2014","journal-title":"Curr Hematol Malig Rep"},{"issue":"Suppl 1","key":"10.1016\/j.pop.2016.07.011_bib3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/ijlh.12353","article-title":"Molecular genetic evaluation of myeloproliferative neoplasms","volume":"37","author":"Azzato","year":"2015","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.pop.2016.07.011_bib4","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.mayocp.2015.05.014","article-title":"Essential thrombocythemia and polycythemia vera: focus on clinical practice","volume":"90","author":"Tefferi","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.pop.2016.07.011_bib5","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/jamaoncol.2015.89","article-title":"Myeloproliferative neoplasms: a contemporary review","volume":"1","author":"Tefferi","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.pop.2016.07.011_bib6","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.beha.2014.07.004","article-title":"Essential thrombocythemia vs. early\/prefibrotic myelofibrosis: why does it matter","volume":"27","author":"Barosi","year":"2014","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.pop.2016.07.011_bib7","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ajh.23690","article-title":"How common are myeloproliferative neoplasms? A systematic review and meta-analysis","volume":"89","author":"Titmarsh","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.pop.2016.07.011_bib8","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2340\/00015555-1959","article-title":"Paraneoplastic itch: an expert position statement from the Special Interest Group (SIG) of the International Forum on the Study of Itch (IFSI)","volume":"95","author":"Weisshaar","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.pop.2016.07.011_bib9","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1200\/JCO.2015.61.6474","article-title":"Polycythemia vera: an appraisal of the biology and management 10 years after the discovery of JAK2 V617F","volume":"33","author":"Stein","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pop.2016.07.011_bib10","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s11899-014-0239-9","article-title":"Quality of life in MPN comes of age as a therapeutic target","volume":"9","author":"Scherber","year":"2014","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.pop.2016.07.011_bib11","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1007\/s00277-014-2205-y","article-title":"Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options","volume":"93","author":"Stein","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.pop.2016.07.011_bib12","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.beha.2014.07.006","article-title":"Assessing disease burden in patients with classic MPNs","volume":"27","author":"Geyer","year":"2014","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.pop.2016.07.011_bib13","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.ejim.2015.03.007","article-title":"The clinical and laboratory evaluation of the patient with erythrocytosis","volume":"26","author":"Lee","year":"2015","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.pop.2016.07.011_bib14","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","article-title":"Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel","volume":"110","author":"Tefferi","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.pop.2016.07.011_bib15","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.pop.2016.07.011_bib16","first-page":"172","article-title":"Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera","volume":"23","author":"Tartaglia","year":"1986","journal-title":"Semin Hematol"},{"issue":"10","key":"10.1016\/j.pop.2016.07.011_bib17","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera","volume":"23","author":"Marchioli","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.pop.2016.07.011_bib18","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/bjh.12117","article-title":"Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a population-based study of 327 patients","volume":"160","author":"Bonicelli","year":"2013","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.pop.2016.07.011_bib19","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1365-2141.2007.06674.x","article-title":"Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation","volume":"138","author":"Gangat","year":"2007","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.pop.2016.07.011_bib20","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.pop.2016.07.011_bib21","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.pop.2016.07.011_bib22","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","article-title":"Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera","volume":"112","author":"Kiladjian","year":"2008","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.pop.2016.07.011_bib23","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.pop.2016.07.011_bib24","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1200\/JCO.2011.36.0792","article-title":"Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980","volume":"29","author":"Kiladjian","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pop.2016.07.011_bib25","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1182\/blood-2011-02-339002","article-title":"Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients","volume":"117","author":"Carobbio","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.pop.2016.07.011_bib26","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1182\/blood-2012-01-403279","article-title":"A\u00a0prognostic model to predict survival\u00a0in\u00a0867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on myelofibrosis research and treatment","volume":"120","author":"Passamonti","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.pop.2016.07.011_bib27","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an international prognostic score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.pop.2016.07.011_bib28","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","article-title":"Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis","volume":"332","author":"Cortelazzo","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pop.2016.07.011_bib29","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.pop.2016.07.011_bib30","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40259-016-0170-9","article-title":"Anagrelide and mutational status in essential thrombocythemia","volume":"30","author":"Iurlo","year":"2016","journal-title":"BioDrugs"},{"key":"10.1016\/j.pop.2016.07.011_bib31","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1182\/blood-2006-03-009860","article-title":"High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a","volume":"108","author":"Kiladjian","year":"2006","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.pop.2016.07.011_bib32","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1182\/blood-2015-07-659060","article-title":"Clinical and molecular response to interferon-alpha therapy in essential thrombocythemia patients with CALR mutations","volume":"126","author":"Verger","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.pop.2016.07.011_bib33","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet","volume":"29","author":"Barbui","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"10.1016\/j.pop.2016.07.011_bib34","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1182\/blood-2015-01-624536","article-title":"JAK2V617F complete molecular remission in polycythemia vera\/essential thrombocythemia patients treated with ruxolitinib","volume":"125","author":"Pieri","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.pop.2016.07.011_bib35","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.amjmed.2004.06.032","article-title":"Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia","volume":"117","author":"Passamonti","year":"2004","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.pop.2016.07.011_bib36","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1046\/j.1365-2141.2002.03688.x","article-title":"Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients","volume":"118","author":"Cervantes","year":"2002","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.pop.2016.07.011_bib37","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4065\/81.2.159","article-title":"Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors","volume":"81","author":"Wolanskyj","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.pop.2016.07.011_bib38","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/MOH.0000000000000122","article-title":"Clinical and molecular genetic characterization of myelofibrosis","volume":"22","author":"Hobbs","year":"2015","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.pop.2016.07.011_bib39","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1182\/blood-2007-12-128454","article-title":"The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal","volume":"112","author":"Spivak","year":"2008","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.pop.2016.07.011_bib40","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.pop.2016.07.011_bib41","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A\u00a0double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.pop.2016.07.011_bib42","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","article-title":"Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis","volume":"122","author":"Cervantes","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.pop.2016.07.011_bib43","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.critrevonc.2015.11.004","article-title":"Myeloproliferative neoplasms: current molecular biology and genetics","volume":"98","author":"Saeidi","year":"2016","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Primary Care: Clinics in Office Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0095454316300513?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0095454316300513?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T11:57:10Z","timestamp":1536235030000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0095454316300513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S0095454316300513"],"URL":"https:\/\/doi.org\/10.1016\/j.pop.2016.07.011","relation":{},"ISSN":["0095-4543"],"issn-type":[{"value":"0095-4543","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Polycythemia and Thrombocytosis","name":"articletitle","label":"Article Title"},{"value":"Primary Care: Clinics in Office Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pop.2016.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}